Orzax 5-HTP Complex
Natural health product licensed in Canada
- Licence holder
- Orzax Inc.
- NPN or DIN-HM
- 80140875
- Status
- Active licence
- Licence date
- 12 May 2025
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Riboflavine Source : Riboflavin 5'-phosphate de sodium | 1.4 mg | 2,800 µg |
| Folate Source : Acide folique | 200 Microgrammes | Not calculated |
| L-5-Hydroxytryptophane Source : 5-HTP | 50 mg | Not calculated |
| L-Tryptophane Source : L-Tryptophane | 50 mg | Not calculated |
| Rhodiola rosea Source : Rhodiola rosea - Racine Potency : 1 % Rosavins | 50 mg | Not calculated |
Non-medicinal ingredients
Stéarate de magnésium, Dioxyde de silicium, Hypromellose, Cellulose microcristalline
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 18 years | 2 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps (to) relieve sleep disturbances associated with mood imbalance. Helps in energy metabolism/(and) tissue formation. Helps to form red blood cells. Helps to maintain/support healthy mucous membranes. Helps to maintain/support normal metabolism of iron. Helps to maintain/support normal red blood cells. Helps to maintain/support the body's ability to metabolize nutrients. Helps to reduce the risk of neural tube defects when taken daily at least three months prior to becoming pregnant and during early pregnancy. Helps to support normal early fetal development (brain and spinal cord). Source of/Provides antioxidants. Source of (an) (essential) amino acid(s) involved in muscle protein synthesis. Source of (an) essential amino acid(s) for the maintenance of good health.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80140875
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- L-5-Hydroxytryptophane
Read the warning, when it applies and the studies cited
5-HTP
Route of administration: Oral
Cautions and warnings
Condition of application: All uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking carbidopa or health products with serotonergic activity such as mood balance supplements, cough medication containing dextromethorphan, pain killers or medications for nausea or migraine (Mayo Clinic Staff 2022; Patel and Marzella 2017; Turner et al 2006).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product exercise caution while driving or using machinery, as you may experience drowsiness (Berardi et al. 2002).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All uses (excluding weight management).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Condition of application: Weight management.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Condition of application: Healthy mood balance; Fibromyalgia symptoms.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a psychological disorder such as anxiety or depression.
Contraindications
Condition of application: All uses.
Do not use if you have scleroderma (Lampert et al. 1992; Sternberg et al. 1980).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Do not use if you are taking antidepressants (Mayo Clinic Staff 2022; Patel and Marzella 2017).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Weight management.
Do not use if you are pregnant (HC 2010).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
When using this product you may experience gastrointestinal discomfort/disturbances (Turner et al. 2006; Byerley et al. 1987).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience skin hardening, pain or stiffness of muscles or joints, tremors, agitation/confusion, or an increased heart rate (Boyer 2023; Varga 2023; Mayo Clinic Staff 2022; Patel and Marzella 2017; Das et al. 2004; Erner et al. 2003; Lampert et al. 1992; Sternberg et al. 1980).
8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.